WEKO3
-
RootNode
アイテム
Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases
http://hdl.handle.net/10091/00019349
http://hdl.handle.net/10091/00019349e6174109-e5cc-4c8c-aa50-3b4edb1f8198
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
Applications_Genetically_Modified_immunobiotics.pdf (1.4 MB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2017-02-01 | |||||||||
| タイトル | ||||||||||
| タイトル | Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases | |||||||||
| 言語 | ||||||||||
| 言語 | eng | |||||||||
| DOI | ||||||||||
| 関連識別子 | https://doi.org/10.3389/fimmu.2017.00022 | |||||||||
| 関連名称 | 10.3389/fimmu.2017.00022 | |||||||||
| キーワード | ||||||||||
| 主題 | probiotics, immunobiotics, IBD, gmLAB, gm-immunobiotics | |||||||||
| 資源タイプ | ||||||||||
| 資源 | http://purl.org/coar/resource_type/c_6501 | |||||||||
| タイプ | journal article | |||||||||
| 著者 |
Shigemori, Suguru
× Shigemori, Suguru
× Shimosato, Takeshi
|
|||||||||
| 信州大学研究者総覧へのリンク | ||||||||||
| 氏名 | Shimosato, Takeshi | |||||||||
| URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.ONLCjFkV.html | |||||||||
| 出版者 | ||||||||||
| 出版者 | Frontiers Media | |||||||||
| 引用 | ||||||||||
| 内容記述 | Frontiers in Immunology. 8:22 (2017) | |||||||||
| 書誌情報 |
Frontiers in Immunology 巻 8, p. 22, 発行日 2017-01-25 |
|||||||||
| 抄録 | ||||||||||
| 内容記述 | Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are chronic inflammatory diseases characterized by dysregulated immune responses of the gastrointestinal tract. In recent years, the incidence of IBDs has increased in developed nations, but their prophylaxis/treatment is not yet established. Site-directed delivery of molecules showing anti-inflammatory properties using genetically modified (gm) probiotics shows promise as a new strategy for the prevention and treatment of IBD. Advantages of gm-probiotics include 1) the ability to use bacteria as a delivery vehicle, enabling safe and long-term use by humans, 2) decreased risks of side effects, and 3) reduced costs. The intestinal delivery of anti-inflammatory proteins such as cytokines and enzymes using Lactococcus lactis has been shown to regulate host intestinal homeostasis depending on the delivered protein-specific machinery. Additionally, clinical experience using interleukin 10-secreting Lactococcus lactis has been shown to be safe and to facilitate biological containment in IBD therapy. On the other hand, some pre-clinical studies have demonstrated that gm-strains of immunobiotics (probiotics strains able to beneficially regulate the mucosal immunity) provide beneficial effects on intestinal inflammation as a result of the synergy between the immunoregulatory effects of the bacterium itself and the anti-inflammatory effects of the delivered recombinant proteins. In this review, we discuss the rapid progression in the development of strategies for the prophylaxis and treatment of IBD using gm-probiotics that exhibit immune regulation effects (gm-immunobiotics). In particular, we discuss the type of strains used as delivery agents. | |||||||||
| 資源タイプ（コンテンツの種類） | ||||||||||
| ISSN | ||||||||||
| 収録物識別子タイプ | ISSN | |||||||||
| 収録物識別子 | 1664-3224 | |||||||||
| 権利 | ||||||||||
| 権利情報 | Copyright © 2017 Shigemori and Shimosato. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | |||||||||
| 出版タイプ | ||||||||||
| 出版タイプ | VoR | |||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||
Share
Cite as
Shigemori, Suguru, Shimosato, Takeshi, 2017, Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases: Frontiers Media, 22– p.
Loading...
